cinacalcet

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism, End Stage Renal Disease

Trial Timeline

Sep 1, 2004 → Feb 1, 2006

NCT ID

NCT00117052

About cinacalcet

cinacalcet is a phase 3 stage product being developed by Amgen for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT00117052. Target conditions include Secondary Hyperparathyroidism, End Stage Renal Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00113958	Phase 2	Completed	—	—	End Stage Renal Disease
NCT02341417	Phase 3	Completed	Jun 10, 2015	Mar 15, 2017	Secondary Hyperparathyroidism, Chronic Kidney Disease
NCT01290029	Phase 1	Completed	Jan 25, 2011	Sep 23, 2015	Chronic Kidney Disease
NCT00928408	Pre-clinical	Completed	Oct 1, 2009	Feb 1, 2012	Hyperparathyroidism, Primary
NCT00431496	Approved	Completed	Sep 1, 2006	Oct 1, 2009	Anemia
NCT00379899	Approved	Completed	Sep 1, 2006	Nov 1, 2009	Chronic Kidney Disease
NCT00117052	Phase 3	Completed	Sep 1, 2004	Feb 1, 2006	Secondary Hyperparathyroidism
NCT00110890	Approved	Completed	May 1, 2004	Sep 1, 2007	End Stage Renal Disease
NCT00113945	Phase 2	Completed	Jul 1, 2003	—	End Stage Renal Disease
NCT00936988	Phase 2	Completed	Nov 1, 2000	Dec 1, 2005	Hyperparathyroidism, Primary

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	52
Fycompa	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	65
KHK7580	Kyowa Kirin	Phase 1	33
KHK7580	Kyowa Kirin	Phase 3	77
KHK7580	Kyowa Kirin	Phase 3	77
Cinacalcet HCl	Kyowa Kirin	Approved	85
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	52
dirucotide + Placebo	Eli Lilly	Phase 2/3	65
dirucotide	Eli Lilly	Phase 2/3	65
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	77
Paricalcitol + Calcifediol	AbbVie	Approved	85
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	85
Birabresib Dose 20 mg	Merck	Phase 1	33
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	77
Ranibizumab	Novartis	Approved	85
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	85

Other Products from Amgen